Thomas E. Witzig

62.0k total citations · 4 hit papers
778 papers, 34.1k citations indexed

About

Thomas E. Witzig is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Thomas E. Witzig has authored 778 papers receiving a total of 34.1k indexed citations (citations by other indexed papers that have themselves been cited), including 476 papers in Pathology and Forensic Medicine, 295 papers in Genetics and 284 papers in Oncology. Recurrent topics in Thomas E. Witzig's work include Lymphoma Diagnosis and Treatment (456 papers), Chronic Lymphocytic Leukemia Research (263 papers) and Multiple Myeloma Research and Treatments (138 papers). Thomas E. Witzig is often cited by papers focused on Lymphoma Diagnosis and Treatment (456 papers), Chronic Lymphocytic Leukemia Research (263 papers) and Multiple Myeloma Research and Treatments (138 papers). Thomas E. Witzig collaborates with scholars based in United States, Italy and Canada. Thomas E. Witzig's co-authors include Philip R. Greipp, S. Vincent Rajkumar, Stephen M. Ansell, Robert A. Kyle, Martha Q. Lacy, Morie A. Gertz, John A. Lust, Angela Dispenzieri, Rafaël Fonseca and Thomas M. Habermann and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Thomas E. Witzig

744 papers receiving 33.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Review of 1027 Patients With Newly Diagnosed Multiple Myeloma

2003 1.6k citations Robert A. Kyle, Morie A. Gertz et al. profile →
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 841 citations Thomas E. Witzig, Leo I. Gordon et al. Journal of Clinical Oncology profile →
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

2004 639 citations Angela Dispenzieri, Morie A. Gertz et al. Journal of Clinical Oncology profile →
Rituximab for IgG4-related disease: a prospective, open-label trial

2015 444 citations Thomas E. Witzig et al. profile →

Peers

Countries citing papers authored by Thomas E. Witzig

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Witzig more than expected).

Fields of papers citing papers by Thomas E. Witzig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Witzig. The network helps show where Thomas E. Witzig may publish in the future.

Co-authorship network of co-authors of Thomas E. Witzig

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Witzig. A scholar is included among the top collaborators of Thomas E. Witzig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Witzig. Thomas E. Witzig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma 2025 ·Journal of Clinical Investigation ·Jithma P. Abeykoon, Shuhei Asada, Gui‐Qi Zhu, (unknown), Lisa A. Moreau, Divya Iyer, (unknown), Kalindi Parmar, (unknown), (unknown), (unknown), Michelle K. Manske, (unknown), Rebecca L. King, James R. Cerhan, Xiaosheng Wu, Zhenkun Lou, Geoffrey I. Shapiro, Thomas E. Witzig, Alan D. D’Andrea	1
2	CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma 2024 ·British Journal of Haematology ·Emil Kumar, Koorosh Korfi, Findlay Bewicke‐Copley, (unknown), James A. Heward, Thomas E. Witzig, (unknown), Stephen M. Ansell, (unknown), Andrew Clear, Alejo Efeyan, Michael R. Green, R. Siebert, Barrie Peck, Maria Calaminici, Jun Wang, Sonali M. Smith, Anne J. Novak, Jude Fitzgibbon, Jessica Okosun	1
3	Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 2024 ·The Oncologist ·Jennifer Gile, Matthew J. Maurer, Gordon Ruan, Jithma P. Abeykoon, (unknown), N Baumann, Molly McMahon, Yi Lin, Thomas E. Witzig	0
4	Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study 2024 ·Blood ·Jacqueline Wang, Jihao Zhou, (unknown), Han W. Tun, Javier Muñoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, (unknown), Catherine Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang	0
5	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study 2022 ·Blood Advances ·Aung M. Tun, Arushi Khurana, Raphael Mwangi, Brian K. Link, Yucai Wang, Andrew L. Feldman, Carrie A. Thompson, Anne J. Novak, José C. Villasboas, Gita Thanarajasingam, Umar Farooq, Sergei Syrbu, Grzegorz S. Nowakowski, Thomas E. Witzig, Stephen M. Ansell, Lisa M. Rimsza, James R. Cerhan, Thomas M. Habermann, Matthew J. Maurer	7
6	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 2020 ·Clinical Cancer Research ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie Chang, Brad S. Kahl	16
7	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia 2020 ·Blood ·Francis K. Buadi, Martha Q. Lacy, Gabriela Pérez, (unknown), Ankit Kansagra, Thomas E. Witzig, (unknown), (unknown), Daniel Auclair, Hearn Jay Cho, Shaji Kumar	1
8	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era 2018 ·Blood ·Yucai Wang, Umar Farooq, Brian K. Link, Mehrdad Hefazi, Cristine Allmer, Matthew J. Maurer, Thomas E. Witzig, Thomas M. Habermann, Stephen M. Ansell, James R. Cerhan, Grzegorz S. Nowakowski	1
9	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas 2015 ·Clinical Cancer Research ·Esteban Braggio, Scott Van Wier, Juhi Ojha, Ellen D. McPhail, Yan W. Asmann, Jan B. Egan, Jackline de Paula Ayres-Silva, David Schiff, M. Beatriz S. Lopes, Paul A. Decker, Riccardo Valdez, Raoul Tibes, Bruce W. Eckloff, Thomas E. Witzig, A. Keith Stewart, Rafaël Fonseca, Brian Patrick O’Neill	150
10	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma 2015 ·Blood ·Thomas E. Witzig, Craig B. Reeder, Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William R. Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Mamta Gupta	83
11	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study 2014 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson, Candido E. Rivera, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Randy D. Gascoyne, Thomas M. Habermann, Thomas E. Witzig	268
12	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma 2013 ·Journal of Clinical Oncology ·Prashant Kapoor, Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, David Dingli, Stephen J. Russell, Suzanne R. Hayman, Thomas E. Witzig, John A. Lust, Nelson Leung, Yi Lin, Steven R. Zeldenrust, Arleigh McCurdy, Philip R. Greipp, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz	120
13	Species D Adenoviruses as Oncolytics against B-cell Cancers 2011 ·Clinical Cancer Research ·Christopher Y. Chen, Julien S. Senac, Eric A. Weaver, Shannon M. May, Diane F. Jelinek, Philip R. Greipp, Thomas E. Witzig, Michael A. Barry	37
14	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report 2011 ·Leukemia & lymphoma ·Thomas E. Witzig, Paul A. S. Fishkin, Leo I. Gordon, Stephanie A. Gregory, Samuel A. Jacobs, Roger M. Macklis, Peter McLaughlin, Oliver W. Press, Andrew D. Zelenetz	25
15	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia 2010 ·Journal of Clinical Oncology ·Irene M. Ghobrial, Morie A. Gertz, Betsy LaPlant, John Camoriano, Suzanne R. Hayman, Martha Q. Lacy, Stacey Chuma, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M. Ansell, Daniel J. DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig B. Reeder, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Thomas E. Witzig	102
16	Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Jennifer L. Kelly, Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan, Alice H. Wang, Thomas E. Witzig, Timothy G. Call, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	34
17	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia 2010 ·Blood ·Tait D. Shanafelt, Matthew T. Drake, Matthew J. Maurer, Cristine Allmer, Kari G. Rabe, Susan L. Slager, George J. Weiner, Timothy G. Call, Brian K. Link, Clive S. Zent, Neil E. Kay, Curtis A. Hanson, Thomas E. Witzig, James R. Cerhan	104
18	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era 2009 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Matthew J. Maurer, Thomas M. Habermann, Stephen M. Ansell, William R. Macon, Kay M. Ristow, Cristine Allmer, Susan L. Slager, Thomas E. Witzig, James R. Cerhan	45
19	Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma 2009 ·Cancer Research ·Zhi‐Zhang Yang, Anne J. Novak, Steven C. Ziesmer, Thomas E. Witzig, Stephen M. Ansell	131
20	Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy 2007 ·Journal of Clinical Oncology ·Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Stephen Revell, Katie D. Vo, Arturo Molina	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact